耐马立巴韦的巨细胞病毒的出现：现实世界中的现实问题？ - Suppr | 超能文献

Development of cytomegalovirus resistant to maribavir: real world, real problem?

作者信息

Kleiboeker Hanna L, Prom Alyson, Paplaczyk Krista

机构信息

Department of Pharmacy, Northwestern Memorial Hospital, Chicago, Illinois, USA.

出版信息

Transpl Infect Dis. 2024 Apr;26(2):e14259. doi: 10.1111/tid.14259. Epub 2024 Mar 2.

DOI:10.1111/tid.14259

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Development of cytomegalovirus resistant to maribavir: real world, real problem?耐马立巴韦的巨细胞病毒的出现：现实世界中的现实问题？

Transpl Infect Dis. 2024 Apr;26(2):e14259. doi: 10.1111/tid.14259. Epub 2024 Mar 2.

2

Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients.在一项评估马拉韦罗治疗移植受者难治或耐药巨细胞病毒感染的 3 期临床试验中评估耐药性。

J Infect Dis. 2024 Feb 14;229(2):413-421. doi: 10.1093/infdis/jiad293.

3

Evaluating Real-World Experience With Maribavir for Treatment of Refractory/Resistant Cytomegalovirus in Renal Transplant Recipients.评估马拉韦罗治疗肾移植受者难治/耐药巨细胞病毒的真实世界经验。

Clin Transplant. 2024 Oct;38(10):e15480. doi: 10.1111/ctr.15480.

4

Comparative Emergence of Maribavir and Ganciclovir Resistance in a Randomized Phase 3 Clinical Trial for Treatment of Cytomegalovirus Infection.在一项治疗巨细胞病毒感染的随机3期临床试验中，马立巴韦与更昔洛韦耐药性的比较出现情况

J Infect Dis. 2025 Mar 17;231(3):e470-e477. doi: 10.1093/infdis/jiae469.

5

Cost-effectiveness of maribavir versus conventional antiviral therapies for post-transplant refractory cytomegalovirus infection with or without genotypic resistance: A US perspective.马利巴韦与传统抗病毒疗法治疗移植后难治性巨细胞病毒感染伴或不伴基因型耐药的成本效益：美国视角。

J Med Virol. 2024 Apr;96(4):e29609. doi: 10.1002/jmv.29609.

6

Real-World Experience With Maribavir for Treatment of Refractory or Resistant Cytomegalovirus Infection in Hematopoietic Cell Transplant Recipients and Hematologic Malignancy Patients.马立巴韦用于治疗造血细胞移植受者和血液系统恶性肿瘤患者难治性或耐药性巨细胞病毒感染的真实世界经验。

Transpl Infect Dis. 2025 Mar-Apr;27(2):e14444. doi: 10.1111/tid.14444. Epub 2025 Jan 18.

7

The emergence of letermovir and maribavir drug-resistant mutations: from clinical trials to real-world studies.来特莫韦和马拉韦罗耐药突变的出现：从临床试验到真实世界研究。

Curr Opin Infect Dis. 2024 Dec 1;37(6):536-546. doi: 10.1097/QCO.0000000000001065. Epub 2024 Sep 27.

8

Refractory/Resistant Cytomegalovirus Infection in Transplant Recipients: An Update.移植受者难治性/耐药巨细胞病毒感染：更新。

Viruses. 2024 Jul 5;16(7):1085. doi: 10.3390/v16071085.

9

Current Perspectives on Letermovir and Maribavir for the Management of Cytomegalovirus Infection in Solid Organ Transplant Recipients.目前关于来特莫韦和马拉韦罗治疗实体器官移植受者巨细胞病毒感染的观点。

Drug Des Devel Ther. 2024 Sep 6;18:3987-4001. doi: 10.2147/DDDT.S265644. eCollection 2024.

10

Population pharmacokinetics and exposure-response relationships of maribavir in transplant recipients with cytomegalovirus infection.移植受者巨细胞病毒感染时马拉维若的群体药代动力学和暴露-反应关系。

J Pharmacokinet Pharmacodyn. 2024 Dec;51(6):887-904. doi: 10.1007/s10928-024-09939-2. Epub 2024 Sep 27.

引用本文的文献

1

Dual Resistance to Maribavir and Ganciclovir in Transplant Recipients.移植受者对马立巴韦和更昔洛韦的双重耐药性

Viruses. 2025 Mar 14;17(3):421. doi: 10.3390/v17030421.